S. Vincent Rajkumar

Also affiliated with WinnMed, Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 46 papers. Top paper: “Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial”.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Blood(2022)10.1182/blood.2022015851

N/A

1.1DataRank · unranked

1538 citations

Elaine S. Jaffe, James R. Cook, Leticia Quintanilla‐Martínez, Steven H. Swerdlow, Kenneth C. Anderson +68 more

Initial genome sequencing and analysis of multiple myeloma

Nature(2011)10.1038/nature09837

N/A

1.1DataRank · unranked

1438 citations

Michael S. Lawrence, Jonathan J. Keats, Kristian Cibulskis, Carrie Sougnez, Anna C. Schinzel +51 more

Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.3854

N/A

0.864DataRank · unranked

21 citations

Fengmin Zhao, Ju‐Whei Lee, Shu-en Shen, Edward H. Ip, Nathaniel S. O’Connell +12 more

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Blood(2024)10.1182/blood.2024025939

N/A

0.621DataRank · unranked

10 citations

Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar +9 more

Identification of novel genetic loci for risk of multiple myeloma by functional annotation

Leukemia(2023)10.1038/s41375-023-02022-8

N/A

0.312DataRank · unranked

7 citations

Klara Briem, Alyssa Clay‐Gilmour, Wendy Cozen, Asta Försti, Matteo Giaccherini +61 more

Relationship among three common hematological premalignant conditions

Leukemia(2023)10.1038/s41375-023-01914-z

N/A

0.241DataRank · unranked

4 citations

Sameer A. Parikh, Aaron D. Norman, Kari G. Rabe, Rosalie Griffin, Timothy G. Call +14 more

Dose Delays and Treatment Interruptions Secondary to Ocular Toxicity From BCMA-Directed Antibody Drug Conjugate Therapy in Relapsed Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.10.003

N/A

0.165DataRank · unranked

2 citations

Timothy T. Xu, Suheil Albert Atallah‐Yunes, Kenneth J C Lim, Sikander Ailawadhi, Ricardo Parrondo +17 more

Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)

Leukemia(2024)10.1038/s41375-024-02363-y

N/A

0.104DataRank · unranked

1 citations

Huihuang Yan, Suganti Shivaram, Stacey L. Lehman, Neeraj Sharma, James B. Smadbeck +21 more

The Case for Masks

Mayo Clinic Proceedings(2020)10.1016/j.mayocp.2020.04.014

N/A

0DataRank · unranked

2 citations

S. Vincent Rajkumar, Anna Kaltenboeck

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more

Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy

Mayo Clinic Proceedings(2021)10.1016/j.mayocp.2020.06.060

N/A

0DataRank · unranked

38 citations

Shaji Kumar, Angela Dispenzieri, Francis K. Buadi, David Dingli, Martha Q. Lacy +20 more

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0005

N/A

0DataRank · unranked

36 citations

James B. Smadbeck, Nadine Abdallah, Cinthya Zepeda‐Mendoza, Moritz Binder, Kathryn E. Pearce +9 more

The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.02.001

N/A

0DataRank · unranked

17 citations

Ronald S. Go, Rahma Warsame, Bharat Nandakumar, Francis K. Buadi, Angela Dispenzieri +20 more

Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.03.031

N/A

0DataRank · unranked

5 citations

Angela Dispenzieri, Shaji Kumar, Martha Q. Lacy, Francis K. Buadi, David Dingli +15 more

Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.e20016

N/A

0DataRank · unranked

0 citations

Shaji Kumar, David Dingli, Angela Dispenzieri, Martha Q. Lacy, Ronald S. Go +15 more

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

American Journal of Hematology(2022)10.1002/ajh.26590

N/A

0DataRank · unranked

851 citations

S. Vincent Rajkumar

Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.05.004

N/A

0DataRank · unranked

65 citations

Amylou C. Dueck, Gita Thanarajasingam, Joan M. Griffin, Carrie A. Thompson, Urshila Durani +12 more

Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.030

N/A

0DataRank · unranked

7 citations

Shaji Kumar, Angela Dispenzieri, Dragan Jevremović, Francis K. Buadi, David Dingli +21 more

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms

Blood Cancer Journal(2022)10.1038/s41408-022-00706-5

N/A

0DataRank · unranked

4 citations

Shulan Tian, Susan M. Geyer, Neeraj Sharma, Celine M. Vachon, Yael Kusne +7 more

The Path Forward in Multiple Myeloma: 2021 Jan Waldenstrom Award Lecture

Clinical Lymphoma Myeloma & Leukemia(2022)10.1016/j.clml.2022.04.021

N/A

0DataRank · unranked

1 citations

S. Vincent Rajkumar

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Sarcopenia identified by computed tomography (CT) imaging using a machine learning–based convolutional neural network (CNN) algorithm impacts survival in patients with newly diagnosed multiple myeloma (NDMM).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.110

N/A

0DataRank · unranked

1 citations

Nadine Abdallah, Shaji Kumar, Angela Dispenzieri, David Dingli, Prashant Kapoor +15 more

Smoldering Multiple Myeloma

Hematology/Oncology Clinics of North America(2023)10.1016/j.hoc.2023.12.001

N/A

0DataRank · unranked

25 citations

P. Leif Bergsagel, Shaji Kumar, S. Vincent Rajkumar

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood(2023)10.1182/blood.2023021187

N/A

0DataRank · unranked

14 citations

Shaji Kumar, Linda B. Baughn, Angela Dispenzieri, Patricia T. Greipp, Rhett P. Ketterling +28 more

Current approach to Waldenström macroglobulinemia

Blood Reviews(2023)10.1016/j.blre.2023.101129

N/A

0DataRank · unranked

12 citations

S. Vincent Rajkumar, Prashant Kapoor

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians

Blood Cancer Journal(2023)10.1038/s41408-023-00937-0

N/A

0DataRank · unranked

11 citations

Bo Wang, Larry D. Anderson, Georgia McCaughan, Nikita Mehra, Andrew J. Cowan +3 more

Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm

Genetics in Medicine Open(2023)10.1016/j.gimo.2023.100816

N/A

0DataRank · unranked

2 citations

Hongwei Tang, Neeraj Sharma, Huihuang Yan, Shulan Tian, James B. Smadbeck +17 more

Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management

American Journal of Hematology(2024)10.1002/ajh.27422

N/A

0DataRank · unranked

421 citations

S. Vincent Rajkumar

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Journal of Clinical Oncology(2025)10.1200/jco-24-01893

N/A

0DataRank · unranked

142 citations

Faith E. Davies, Mehmet Samur, Jill Corre, Mattia D’Agostino, Martin Kaiser +41 more

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

Nature Genetics(2025)10.1038/s41588-025-02292-1

N/A

0DataRank · unranked

11 citations

Marcella Kaddoura, Alexandra M. Poos, Linda B. Baughn, Bachisio Ziccheddu, Marc-Andrea Bärtsch +27 more

Risk of lymphoid malignancy associated with cancer predisposition genes

Blood Cancer Journal(2025)10.1038/s41408-025-01283-z

N/A

0DataRank · unranked

8 citations

Raphael Mwangi, Dennis P. Robinson, Cristine Allmer, Allison Rosenthal, Thomas M. Habermann +95 more

Monoclonal Gammopathies in Africa

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.05.023

N/A

0DataRank · unranked

2 citations

Lateef Odukoya, Francis K. Buadi, S. Vincent Rajkumar, Shaji Kumar, Celine M. Vachon +4 more

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia

Blood Cancer Journal(2025)10.1038/s41408-025-01442-2

N/A

0DataRank · unranked

2 citations

Shaji K. Kumar, Samhar Alouch, Adrian Almodovar-Diaz, A. Dispenzieri, D. Jevremovic +23 more

Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes

Blood Cancer Journal(2025)10.1038/s41408-025-01349-y

N/A

0DataRank · unranked

1 citations

Daniel George Packard, Suheil Albert Atallah‐Yunes, Ahauve Orusa, Shinichiro Suzuki, Shaji Kumar +23 more

Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance

Blood Cancer Journal(2025)10.1038/s41408-025-01417-3

N/A

0DataRank · unranked

1 citations

Udit Yadav, Kishore Garapati, Kiran K. Mangalaparthi, Yogesh Chawla, Julia E. Wiedmeier +8 more

Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees

Cancers(2025)10.3390/cancers17223611

N/A

0DataRank · unranked

0 citations

Nicola J. Camp, Xiaomu Wei, Angel Earle, Aaron D. Norman, Jason P. Sinnwell +14 more

Multiple myeloma current treatment algorithms

Blood Cancer Journal(2020)10.1038/s41408-020-00359-2

N/A

0DataRank · unranked

360 citations

Shaji Kumar, S. Vincent Rajkumar

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Blood Cancer Journal(2020)10.1038/s41408-020-0311-8

N/A

0DataRank · unranked

252 citations

Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar +8 more

Medication Shortages During the COVID-19 Crisis

Mayo Clinic Proceedings(2020)10.1016/j.mayocp.2020.04.001

N/A

0DataRank · unranked

117 citations

S. Vincent Rajkumar, Esther K. Choo

The High Cost of Insulin in the United States: An Urgent Call to Action

Mayo Clinic Proceedings(2020)10.1016/j.mayocp.2019.11.013

N/A

0DataRank · unranked

50 citations

S. Vincent Rajkumar

Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.08.003

N/A

0DataRank · unranked

13 citations

Teresa K. Kimlinger, Kelli Gyotoku, Matthew Smith, S. Vincent Rajkumar, Shaji Kumar +1 more

Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance

Blood Advances(2020)10.1182/bloodadvances.2020001435

N/A

0DataRank · unranked

25 citations

Michelle A.T. Hildebrandt, Elizabeth E. Brown, Jonathan N. Hofmann, John J. Spinelli, Graham G. Giles +19 more

The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias

Blood Cancer Journal(2020)10.1038/s41408-020-0294-5

N/A

0DataRank · unranked

7 citations

Zhuo Li, Kathryn E. Pearce, Celine M. Vachon, Mei‐Yin C. Polley, Jonathan J. Keats +10 more

Leaks of Clinical Trial Data and Research Integrity

Mayo Clinic Proceedings(2020)10.1016/j.mayocp.2020.05.007

N/A

0DataRank · unranked

4 citations

Priya Sampathkumar, S. Vincent Rajkumar